Development of a Syngeneic In Vivo Tumor Model and its Use in Evaluating a Novel P-Glycoprotein Modulator, PGP-4008

Oncology Research

Volumn 14, Issue 1, 2003, Pages 49-60

  Lee, Brian D ^a   French, Kevin J ^a   Zhuang, Yan ^a   Smith, Charles D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Mouse solid tumor model; Multidrug resistance; P Glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; GLYCOPROTEIN P MODULATOR; MULTIDRUG RESISTANCE PROTEIN 1; N (1 BENZYL 2,3 DIHYDRO 1H PYRROLO[2,3 B]QUINOLIN 4 YL) 2 PHENYLACETAMIDE; NEW DRUG; PACLITAXEL; PGP 4008; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; CANCER GRAFT; CANCER INHIBITION; CARCINOGENICITY; CELL LEVEL; CELL STRAIN; CELL STRAIN JC; CELL STRAIN TIB 75; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; IC 50; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR ACCUMULATION; ISOGRAFT; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; SYNGENEIC IN VIVO TUMOR MODEL; TUMOR GROWTH; TUMOR MODEL; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 0842348985     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000003108748603     Document Type: Article

References (31)

1. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-162; 1976.
2. Taylor, J. C.; Horvath, A. R.; Higgins, C. F.; Begley, G. S. The multidrug resistance P-glycoprotein. Oligomeric state and intramolecular interactions. J. Biol. Chem. 276:36075-36078; 2001.
3. Horio, M.; Gottesman, M.; Pastan, I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 85:3580-3584; 1988.
4. Kartner, N.; Riordan, J. R.; Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288; 1983.
5. Ling, V. Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40:S3-8; 1997.
6. van de Vrie, W.; Marquet, R. L.; Stoter, G.; De Bruijn, E. A.; Eggermont, A. M. In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit. Rev. Clin. Lab. Sci. 35:1-57; 1998.
7. Trock, B. J.; Leonessa, F.; Clarke, R. Multidrug resistance in breast cancer: A meta-analysis of MDRI/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 89:917-931; 1997.
8. Tan, B. Multidrug resistance transporters and modulation. Appl. Biochem. Biotechnol. 87:233-245; 2000.
9. Sikic, B.; Fisher, G.; Lum, B.; Halsey, J.; Beketic-Oreskovic, L.; Chen, G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40:S13-S19; 1997.
10. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602; 1993.
11. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:4171-4179; 1996.
12. Newman, M. J.; Rodarte, J. C.; Benbatoul, K. D.; Romano, S. J.; Zhang, C.; Krane, S.; Moran, E. J.; Uyeda, R. T.; Dixon, R.; Guns, E. S.; Mayer, L. D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 60:2964-2972; 2000.
13. Lawrence, D. S.; Copper, J. E.; Smith, C. D. Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. J. Med. Chem. 44:594-601; 2001.
14. Smith, C. D. Azabicyclooctane compositions and methods for enhancing chemotherapy. US Patent Office; 2001.
15. Johnson, R.; Chitnis, M.; Embrey, W.; Gregory, E. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukaemia. Cancer Treat. Rep. 62:1535-1547; 1978.
16. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972; 1981.
17. Plumb, J.; Wishart, G.; Setanoians, A.; Morrison, J.; Hamilton, T.; Bicknell, S.; Kaye, S. Identification of a multi-drug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumor xenograft. Biochem. Pharmacol. 47:257-266; 1994.
18. Mistry, P.; Plumb, J.; Eccles, S.; Watson, S.; Dale, I.; Ryder, H.; Box, G.; Chariton, P.; Templeton, D.; Bevan, P. B. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br. J. Cancer 79:1672-1678; 1999.
19. Watanabe, T.; Tsuge, H.; Oh-Hara, T.; Naito, M.; Tsuruo, T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 34:235-241; 1995.
20. Spoelstra, E.; Dekker, H.; Schuurhuis, G.; Broxterman, H.; Lankelma, J. P-glycoprotein efflux pump involved in-the mechanism of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem. Pharmacol. 41:349-359; 1991.
21. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1990.
22. Smith, C. D.; Zilfou, J. T.; Stratmann, K.; Patterson, G. M.; Moore, R. E. Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance. Mol. Pharmacol. 47:241-247; 1995.
23. Miedel, M.; Hulmes, J.; Pan, Y. The use of fluorescamine as a detection reagent in protein microcharacterization. J. Biochem. Biophys. Methods 18: 37-52; 1989.
24. Gros, P.; Raymond, M.; Bell, J.; Housman, D. Cloning and characterization of a second member of the mouse mdr gene family. Mol. Cell. Biol. 8:2770-2778; 1988.
25. Chao, T. Y.; Chu, T. M. Characterization of a new spontaneously developed murine mammary adenocarcinoma in syngeneic BALB/c hosts. In Vitro Cell Dev. Biol. 25:621-626; 1989.
26. Twentyman, P. R. A possible role for cyclosporins in cancer chemotherapy. Anticancer Res. 8:985-993; 1988.
27. Boven, E.; Winograd, B.; Berger, D. P.; Dumont, M. P.; Braakhuis, B. J.; Fodstad, O.; Langdon, S.; Fiebig, H. H. Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study. Cancer Res. 52:5940-5947; 1992.
28. Zilfou, J. T.; Smith, C. D. Differential interactions of cytochalasins with P-glycoprotein. Oncol. Res. 7:435-443; 1995.
29. Dinh, T. Q.; Smith, C. D.; Du, X.; Armstrong, R. W. Design, synthesis, and evaluation of the multidrug resistance-reversing activity of D-glucose mimetics of hapalosin. J. Med. Chem. 41:981-987; 1998.
30. Smith, C. D.; Myers, C. B.; Zilfou, J. T.; Smith, S. N.; Lawrence, D. S. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein. Oncol. Res. 12:219-229; 2000.
31. Xia, Z.; Smith, C. D. Total synthesis of dendroamide A, a novel cyclic peptide that reverses multiple drug resistance. J. Org. Chem. 66:3459-3466; 2001.